Literature DB >> 3760902

Beneficial effect of physostigmine on clinical amnesic behaviour and neuropsychological test results in a patient with a post-encephalitic amnesic syndrome.

C E Catsman-Berrevoets, F Van Harskamp, A Appelhof.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3760902      PMCID： PMC1029023          DOI： 10.1136/jnnp.49.9.1088

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  10 in total

1.  Persistent memory defect following encephalitis.

Authors:  F C ROSE; C P SYMONDS
Journal:  Brain       Date:  1960       Impact factor: 13.501

2.  Evaluating storage, retention, and retrieval in disordered memory and learning.

Authors:  H Buschke; P A Fuld
Journal:  Neurology       Date:  1974-11       Impact factor: 9.910

3.  Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease.

Authors:  O Muramoto; M Sugishita; K Ando
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-05       Impact factor: 10.154

4.  The anterograde and retrograde retrieval ability of a patient with amnesia due to encephalitis.

Authors:  L S Cermak; M O'Connor
Journal:  Neuropsychologia       Date:  1983       Impact factor: 3.139

5.  [Kimura's recurring figures test: standardization on a german population-sample (author's transl)].

Authors:  W Hartje; H Rixecker
Journal:  Nervenarzt       Date:  1978-06       Impact factor: 1.214

6.  Lecithin and physostigmine for posttraumatic memory and cognitive deficits.

Authors:  R G Walton
Journal:  Psychosomatics       Date:  1982-04       Impact factor: 2.386

7.  Behaviour disturbances during recovery from herpes simplex encephalitis.

Authors:  R Greenwood; A Bhalla; A Gordon; J Roberts
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-09       Impact factor: 10.154

8.  Oral physostigmine and lecithin improve memory in Alzheimer disease.

Authors:  L J Thal; P A Fuld; D M Masur; N S Sharpless
Journal:  Ann Neurol       Date:  1983-05       Impact factor: 10.422

9.  Oral physostigmine treatment of patients with Alzheimer's disease.

Authors:  R C Mohs; B M Davis; C A Johns; A A Mathé; B S Greenwald; T B Horvath; K L Davis
Journal:  Am J Psychiatry       Date:  1985-01       Impact factor: 18.112

10.  Memory enhancement after physostigmine treatment in the amnesic syndrome.

Authors:  B H Peters; H S Levin
Journal:  Arch Neurol       Date:  1977-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.